Skip to main content

Advertisement

SpringerLink
Log in

Role of hypertension in progression of pediatric CKD

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Hypertension is frequent in children with chronic kidney disease (CKD). Its prevalence varies according to CKD stage and cause. It is relatively uncommon in children with congenital kidney disease, while acquired kidney disease is associated with a higher prevalence of hypertension. Studies in children with CKD utilizing ambulatory blood pressure monitoring also showed a high prevalence of masked hypertension. Uncontrolled and longstanding hypertension in children is associated with progression of CKD. Aggressive treatment of high blood pressure should be an essential part of care to delay CKD progression in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mitsnefes M, Ho PL, McEnery PT (2003) Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 14:2618–2622

    Article  PubMed  Google Scholar 

  2. Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, Warady BA (2008) Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 52:631–637

    Article  CAS  PubMed  Google Scholar 

  3. Kogon AJ, Pierce CB, Cox C, Brady TM, Mitsnefes MM, Warady BA, Furth SL, Flynn JT (2014) Nephrotic-range proteinuria is strongly associated with poor blood pressure control in pediatric chronic kidney disease. Kidney Int 85:938–944

    Article  PubMed  Google Scholar 

  4. Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Moller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650

  5. Samuels J, Ng D, Flynn JT, Mitsnefes M, Poffenbarger T, Warady BA, Furth S, Chronic Kidney Disease in Children Study Group (2012) Ambulatory blood pressure patterns in children with chronic kidney disease. Hypertension 60:43–50

  6. Schaefer F, Doyon A, Azukaitis K, Bayazit A, Canpolat N, Duzova A, Niemirska A, Sozeri B, Thurn D, Anarat A, Ranchin B, Litwin M, Caliskan S, Candan C, Baskin E, Yilmaz E, Mir S, Kirchner M, Sander A, Haffner D, Melk A, Wuhl E, Shroff R, Querfeld U, 4C Study Consortium (2017) Cardiovascular phenotypes in children with CKD: the 4C study. Clin J Am Soc Nephrol 12:19–28

    Article  PubMed  Google Scholar 

  7. Duzova A, KarabayBayazit A, Canpolat N, Niemirska A, Kaplan Bulut I, Azukaitis K, Karagoz T, Oguz B, Erdem S, Anarat A, Ranchin B, Shroff R, Djukic M, Harambat J, Yilmaz A, Yildiz N, Ozcakar B, Buscher A, Lugani F, Wygoda S, Tschumi S, Zaloszyc A, Jankauskiene A, Laube G, Galiano M, Kirchner M, Querfeld U, Melk A, Schaefer F, Wuhl E, 4C Study Consortium (2019) Isolated nocturnal and isolated daytime hypertension associate with altered cardiovascular morphology and function in children with chronic kidney disease: findings from the Cardiovascular Comorbidity in Children with Chronic Kidney Disease study. J Hypertens 37:2247–2255

    Article  PubMed  Google Scholar 

  8. Barletta GM, Pierce C, Mitsnefes M, Samuels J, Warady BA, Furth S, Flynn J (2018) Is blood pressure improving in children with chronic kidney disease? A Period Analysis. Hypertension 71:444–450

    Article  CAS  PubMed  Google Scholar 

  9. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2012) KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2:339–414

    Google Scholar 

  10. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr (1972) Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584–594

    Article  CAS  PubMed  Google Scholar 

  11. Blumberg A, Nelp WB, Hegstrom RM, Scribner BH (1967) Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. Lancet 2:69–73

    Article  CAS  PubMed  Google Scholar 

  12. Weir MR, Dzau VJ (1999) The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12:205S-213S

    Article  CAS  PubMed  Google Scholar 

  13. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG (1992) Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912–1918

  14. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA (1999) Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321–1328

  15. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, Wu Y, Peixoto A, Crowley S, Desir GV (2005) Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 115:1275–1280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hussein G, Bughdady Y, Kandil ME, Bazaraa HM, Taher H (2008) Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure. Pediatr Nephrol 23:2025–2030

    Article  PubMed  Google Scholar 

  17. Baylis C (2008) Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294:F1–F9

    Article  CAS  PubMed  Google Scholar 

  18. Lariviere R, Lebel M (2003) Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 81:607–621

    Article  CAS  PubMed  Google Scholar 

  19. Christensen PK, Hommel EE, Clausen P, Feldt-Rasmussen B, Parving HH (1999) Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies. Kidney Int 56:1517–1523

    Article  CAS  PubMed  Google Scholar 

  20. Brenner BM (1985) Nephron adaptation to renal injury or ablation. Am J Physiol 249:F324–F337

    CAS  PubMed  Google Scholar 

  21. Bidani AK, Griffin KA (2004) Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 44:595–601

    Article  CAS  PubMed  Google Scholar 

  22. Johnson RJ, Lanaspa MA, Gabriela Sanchez-Lozada L, Rodriguez-Iturbe B (2015) The discovery of hypertension: evolving views on the role of the kidneys, and current hot topics. Am J Physiol Renal Physiol 308:F167–F178

    Article  CAS  PubMed  Google Scholar 

  23. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811–1821

  24. Franco MC, Christofalo DM, Sawaya AL, Ajzen SA, Sesso R (2006) Effects of low birth weight in 8- to 13-year-old children: implications in endothelial function and uric acid levels. Hypertension 48:45–50

    Article  CAS  PubMed  Google Scholar 

  25. Weaver DJ Jr (2019) Uric acid and progression of chronic kidney disease. Pediatr Nephrol 34:801–809

    Article  PubMed  Google Scholar 

  26. Raine AE, Bedford L, Simpson AW, Ashley CC, Brown R, Woodhead JS, Ledingham JG (1993) Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 43:700–705

    Article  CAS  PubMed  Google Scholar 

  27. Rostand SG, DrÅeke TB (1999) Parathyroid hormone, vitamin D and cardiovascular disease in chronic renal failure. Kidney Int 56:383–392

    Article  CAS  PubMed  Google Scholar 

  28. de Borst MH, Vervloet MG, ter Wee PM, Navis G (2011) Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 22:1603–1609

    Article  PubMed  PubMed Central  Google Scholar 

  29. Schärer K (1999) Hypertension in children and adolescents. In: Malluche HH, Sawaya BP, Hakim RM, Sayegh MH (eds) Clinical nephrology, dialysis and transplantation: a continuously updated textbook. Dustri-Verlag, Deisenhofen, pp 1–28

    Google Scholar 

  30. Massella L, Mekahli D, Paripovic D, Prikhodina L, Godefroid N, Niemirska A, Agbas A, Kalicka K, Jankauskiene A, Mizerska-Wasiak M, Afonso AC, Salomon R, Deschenes G, Ariceta G, Ozcakar ZB, Teixeira A, Duzova A, Harambat J, Seeman T, Hrckova G, Lungu AC, Papizh S, Peco-Antic A, De Rechter S, Giordano U, Kirchner M, Lutz T, Schaefer F, Devuyst O, Wuhl E, Emma F (2018) Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol 13:874–883

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hanratty R, Chonchol M, Havranek EP, Powers JD, Dickinson LM, Ho PM, Magid DJ, Steiner JF (2011) Relationship between blood pressure and incident chronic kidney disease in hypertensive patients. Clin J Am Soc Nephrol 6:2605–2611

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O (1997) Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 349:1117–1123

    Article  CAS  PubMed  Google Scholar 

  33. Warady BA, Abraham AG, Schwartz GJ, Wong CS, Munoz A, Betoko A, Mitsnefes M, Kaskel F, Greenbaum LA, Mak RH, Flynn J, Moxey-Mims MM, Furth S (2015) Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) cohort. Am J Kidney Dis 65:878–888

    Article  PubMed  PubMed Central  Google Scholar 

  34. Reynolds BC, Roem JL, Ng DKS, Matsuda-Abedini M, Flynn JT, Furth SL, Warady BA, Parekh RS (2020) Association of time-varying blood pressure with chronic kidney disease progression in children. JAMA Netw Open 3:e1921213

    Article  PubMed  PubMed Central  Google Scholar 

  35. Dionne JM, Jiang S, Ng DK, Flynn JT, Mitsnefes MM, Furth SL, Warady BA, Samuels JA, Group CKs (2021) Mean arterial pressure and chronic kidney disease progression in the CKiD cohort. Hypertension 78:65–73

    Article  CAS  PubMed  Google Scholar 

  36. Timio M, Venanzi S, Lolli S, Lippi G, Verdura C, Monarca C, Guerrini E (1995) “Non-dipper” hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 43:382–387

    CAS  PubMed  Google Scholar 

  37. Bakhoum CY, Phadke M, Deng Y, Samuels JA, Garimella PS, Furth SL, Wilson FP, Ix JH (2022) Nocturnal dipping and kidney function decline: findings from the CKD in children study. Kidney Int Rep 7:2446–2453

    Article  PubMed  PubMed Central  Google Scholar 

  38. Guzman-Limon ML, Jiang S, Ng D, Flynn JT, Warady B, Furth SL, Samuels JA (2022) Nocturnal hypertension in children with chronic kidney disease is common and associated with progression to kidney replacement therapy. Hypertension 79:2288–2297

    Article  CAS  PubMed  Google Scholar 

  39. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646–661

    Article  CAS  PubMed  Google Scholar 

  40. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572

    Article  CAS  PubMed  Google Scholar 

  41. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877–884

    Article  CAS  PubMed  Google Scholar 

  42. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G, REIN-2 Study Group (2005) Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicenter, randomized controlled trial. Lancet 365:939–946

    Article  PubMed  Google Scholar 

  43. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421–2431

    Article  CAS  PubMed  Google Scholar 

  44. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charlston J, Contreras G, Falkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X, AASK Collaborative Research Group (2010) Intensified blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363:918–929

  45. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116

  46. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:e13–e115

    CAS  PubMed  Google Scholar 

  47. Sinha MD, Gu H, Douiri A, Cansick J, Finlay E, Gilbert R, Kerecuk L, Lunn A, Maxwell H, Morgan H, Shenoy M, Shroff R, Subramaniam P, Tizard J, Tse Y, Rezavi R, Simpson JM, Chowienczyk PJ, HOT-KID study (2023) Intensive compared with less intensive blood pressure control to prevent adverse cardiac remodelling in children with chronic kidney disease (HOT-KID): a parallel-group, open-label, multicentre, randomised, controlled trial. Lancet Child Adolesc Health 7:26–36

    Article  PubMed  PubMed Central  Google Scholar 

  48. Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D, Rascher W, Redon J, Schaefer F, Seeman T, Sinha M, Stabouli S, Webb NJ, Wuhl E, Zanchetti A (2016) 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 34:1887–1920

    Article  CAS  PubMed  Google Scholar 

  49. Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104

    Article  PubMed  Google Scholar 

  50. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM, Subcommittee on screening and management of high blood pressure in children (2017) Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 140:e20171904

    Article  PubMed  Google Scholar 

  51. Kidney Disease: Improving Global Outcomes Blood Pressure Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 99:S1–S87

    Article  Google Scholar 

  52. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nephrologia) (1997) Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857–1863

    Article  Google Scholar 

  53. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73–87

    Article  CAS  PubMed  Google Scholar 

  54. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334:939–945

  55. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, Durand D, Chanard J, Mignon F, Suo JM et al (1994) Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309:833–837

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–364

    Article  CAS  PubMed  Google Scholar 

  57. Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Int Med 160:685–693

    Article  CAS  Google Scholar 

  58. van den Belt SM, Heerspink HJL, Kirchner M, Gracchi V, Thurn-Valsassina D, Bayazit AK, Niemirska A, Canpolat N, Kaplan Bulut I, Azukaitis K, Duzova A, Bacchetta J, Shroff R, Paripovic D, Ozcakar ZB, Fidan K, Erdogan H, Gellermann J, Wuhl E, de Zeeuw D, Melk A, Querfeld U, Schaefer F (2020) Discontinuation of RAAS inhibition in children with advanced CKD. Clin J Am Soc Nephrol 15:625–632

    Article  PubMed  PubMed Central  Google Scholar 

  59. Burgess E, Muirhead N, De Cotret PR, Chiu A, Pichette V, Tobe S, SMART (Supra Maximal Atacand Renal Trial) Investigators (2009) Supramaximal dose of Candesartan in proteinuric kidney disease. J Am Soc Nephrol 20:893–900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Doulton TW, He FJ, MacGregor FA (2005) Systemic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45:880–886

    Article  CAS  PubMed  Google Scholar 

  61. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48:8–20

    Article  CAS  PubMed  Google Scholar 

  62. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleigth P, Anderson C (2008) Renal outcomes with telmisartan, ramipril, or both, in patients at high vascular risk (The ONTARGET study): a multicenter, randomized, double-blind, controlled trial. N Engl J Med 358:1547–1559

  63. Mann JF, Schmieder RF, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, MetsÑrinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET Investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553

    Article  CAS  PubMed  Google Scholar 

  64. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 370:221–229

    Article  CAS  PubMed  Google Scholar 

  65. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W (2003) Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 92:38–42

    Article  CAS  PubMed  Google Scholar 

  66. Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF (2020) Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 10:CD007004

    PubMed  Google Scholar 

  67. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G, FIDELIO-DKD Investigators (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219–2229

  68. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL, FIDELIO-DKD and FIGARO-DKD Investigators (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43:474–484

  69. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM, Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314:884–894

    Article  CAS  PubMed  Google Scholar 

  70. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA (2003) Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 14:3217–3232

    Article  CAS  PubMed  Google Scholar 

  71. Baroletti SA, Gabardi S, Magee CC, Milford EL (2003) Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy 23:788–801

    Article  CAS  PubMed  Google Scholar 

  72. Grzesk G, Wicinski M, Malinowski B, Grzesk E, Manysiak S, Odrowaz-Sypniewska G, Darvish N, Bierwagen M (2012) Calcium blockers inhibit cyclosporine A-induced hyperreactivity of vascular smooth muscle cells. Mol Med Rep 5:1469–1474

    CAS  PubMed  Google Scholar 

  73. Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, Butalia S, Leung AA, Harris KC, Cloutier L, Zarnke KB, Ruzicka M, Hiremath S, Feldman RD, Tobe SW, Campbell TS, Bacon SL, Nerenberg KA, Dresser GK, Fournier A, Burgess E, Lindsay P, Rabkin SW, Prebtani APH, Grover S, Honos G, Alfonsi JE, Arcand J, Audibert F, Benoit G, Bittman J, Bolli P, Cote AM, Dionne J, Don-Wauchope A, Edwards C, Firoz T, Gabor JY, Gilbert RE, Gregoire JC, Gryn SE, Gupta M, Hannah-Shmouni F, Hegele RA, Herman RJ, Hill MD, Howlett JG, Hundemer GL, Jones C, Kaczorowski J, Khan NA, Kuyper LM, Lamarre-Cliche M, Lavoie KL, Leiter LA, Lewanczuk R, Logan AG, Magee LA, Mangat BK, McFarlane PA, McLean D, Michaud A, Milot A, Moe GW, Penner SB, Pipe A, Poppe AY, Rey E, Roerecke M, Schiffrin EL, Selby P, Sharma M, Shoamanesh A, Sivapalan P, Townsend RR, Tran K, Trudeau L, Tsuyuki RT, Vallee M, Woo V, Bell AD, Daskalopoulou SS (2020) Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can J Cardiol 36:596–624

    Article  PubMed  Google Scholar 

  74. Borrelli S, Provenzano M, Gagliardi I, Michael A, Liberti ME, De Nicola L, Conte G, Garofalo C, Andreucci M (2020) Sodium intake and chronic kidney disease. Int J Mol Sci 21:4744

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. McMahon EJ, Campbell KL, Bauer JD, Mudge DW, Kelly JT (2021) Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev 6:CD010070

    PubMed  Google Scholar 

  76. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94:26–39

    Article  CAS  PubMed  Google Scholar 

  77. Piperidou A, Sarafidis P, Boutou A, Thomopoulos C, Loutradis C, Alexandrou ME, Tsapas A, Karagiannis A (2019) The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 37:1334–1343

    Article  CAS  PubMed  Google Scholar 

  78. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R, EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117–127

  79. Piperidou A, Loutradis C, Sarafidis P (2021) SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens 35:12–25

    Article  PubMed  Google Scholar 

  80. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G, ASCEND Study Group (2010) Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21:527–535

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D, SONAR Committees and Investigators (2019) Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393:1937–1947

    Article  CAS  PubMed  Google Scholar 

  82. Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R, DUET Study Group (2018) DUET: a phase 2 study evaluating the efficacy and safety of Sparsentan in patients with FSGS. J Am Soc Nephrol 29:2745–2754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA

    Mark M. Mitsnefes

  2. Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany

    Elke Wühl

Authors
  1. Mark M. Mitsnefes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elke Wühl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Mark M. Mitsnefes or Elke Wühl.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mitsnefes, M.M., Wühl, E. Role of hypertension in progression of pediatric CKD. Pediatr Nephrol 38, 3519–3528 (2023). https://doi.org/10.1007/s00467-023-05894-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-023-05894-1

Keywords

Search

Navigation